MX2021015752A - Profarmacos de moduladores del receptor de nmda. - Google Patents

Profarmacos de moduladores del receptor de nmda.

Info

Publication number
MX2021015752A
MX2021015752A MX2021015752A MX2021015752A MX2021015752A MX 2021015752 A MX2021015752 A MX 2021015752A MX 2021015752 A MX2021015752 A MX 2021015752A MX 2021015752 A MX2021015752 A MX 2021015752A MX 2021015752 A MX2021015752 A MX 2021015752A
Authority
MX
Mexico
Prior art keywords
modulators
nmda receptor
prodrugs
compounds
directed
Prior art date
Application number
MX2021015752A
Other languages
English (en)
Inventor
Mauro Marigo
John Paul Kilburn
Erhad Ascic
Laurent David
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MX2021015752A publication Critical patent/MX2021015752A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a profármacos novedosos de moduladores del receptor de NMDA de fórmula I. Otros aspectos de la invención se refieren a composiciones farmacéuticas que comprenden dichos compuestos y a usos de los compuestos para tratar trastornos neurológicos o trastornos neuropsiquiátricos tales como la depresión.
MX2021015752A 2019-07-03 2020-07-01 Profarmacos de moduladores del receptor de nmda. MX2021015752A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201900822 2019-07-03
PCT/EP2020/068513 WO2021001420A1 (en) 2019-07-03 2020-07-01 Prodrugs of modulators of the nmda receptor

Publications (1)

Publication Number Publication Date
MX2021015752A true MX2021015752A (es) 2022-01-27

Family

ID=71614856

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015752A MX2021015752A (es) 2019-07-03 2020-07-01 Profarmacos de moduladores del receptor de nmda.

Country Status (20)

Country Link
US (2) US11358971B2 (es)
EP (1) EP3994140A1 (es)
JP (1) JP2022538180A (es)
KR (1) KR20220034052A (es)
CN (1) CN114008053A (es)
AR (1) AR119341A1 (es)
AU (1) AU2020299410A1 (es)
BR (1) BR112021003983A2 (es)
CA (1) CA3144303A1 (es)
CL (1) CL2021003534A1 (es)
CO (1) CO2021017154A2 (es)
CR (1) CR20210663A (es)
EC (1) ECSP22003599A (es)
IL (1) IL289576A (es)
JO (1) JOP20210332A1 (es)
MA (1) MA56450A (es)
MX (1) MX2021015752A (es)
PE (1) PE20220136A1 (es)
TW (1) TW202116780A (es)
WO (1) WO2021001420A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026700A (en) 1989-05-16 1991-06-25 Merrell Dow Pharmaceuticals Certain quinolines and thienopyridines as excitatory amino acid antagonists
US5252581A (en) 1992-07-20 1993-10-12 Hoechst-Roussel Pharmaceuticals Inc. Substituted aminothienopyridines, pharmaceutical composition and use
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
AU710575B2 (en) 1994-02-08 1999-09-23 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
JP2002511835A (ja) 1996-06-07 2002-04-16 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド 神経障害および神経病の治療に有用な受容体作動性カルシウムチャネル上の新規部位で活性な化合物
WO1998056752A1 (en) 1997-06-11 1998-12-17 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
JP5852664B2 (ja) * 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
CN103298809B (zh) * 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP3386591B1 (en) * 2015-12-09 2020-06-24 Cadent Therapeutics, Inc. Heteroaromatic nmda receptor modulators and uses thereof
US11274107B2 (en) * 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor

Also Published As

Publication number Publication date
CN114008053A (zh) 2022-02-01
CR20210663A (es) 2022-02-22
CA3144303A1 (en) 2021-01-07
IL289576A (en) 2022-03-01
ECSP22003599A (es) 2022-02-25
AR119341A1 (es) 2021-12-09
MA56450A (fr) 2022-05-11
CL2021003534A1 (es) 2022-08-19
KR20220034052A (ko) 2022-03-17
TW202116780A (zh) 2021-05-01
US20210047342A1 (en) 2021-02-18
JOP20210332A1 (ar) 2023-01-30
PE20220136A1 (es) 2022-01-27
US11358971B2 (en) 2022-06-14
US20220213117A1 (en) 2022-07-07
AU2020299410A1 (en) 2022-02-03
JP2022538180A (ja) 2022-08-31
EP3994140A1 (en) 2022-05-11
CO2021017154A2 (es) 2022-01-17
BR112021003983A2 (pt) 2022-03-15
WO2021001420A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
MX2020007383A (es) Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47.
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
CR20220207A (es) Compuestos terapéuticos y métodos de uso
AU2018243836A1 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
PH12021550743A1 (en) Boron containing pde4 inhibitors
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
MX2021000762A (es) Derivados de triazoloquinoxalina sustituida.
ZA202001295B (en) Thiazolopyridine derivatives as adenosine receptor antagonists
CR20200346A (es) Oligonucleótidos para modular la expresión de tmem106b
SA520420046B1 (ar) مركبات بيريدازينون ثلاثية الحلقة مندمجة وعقاقير أولية منها مفيدة لعلاج الإصابات الفيروسة المخاطية القويمة
MX2021008510A (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina.
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
WO2020092102A3 (en) 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of the m4 muscarinic acetylcholine receptor
CR20210663A (es) Profármacos de moduladores del receptor de nmda
PH12021550258A1 (en) Cdk8/19 inhibitors
MX2021015742A (es) Moduladores del receptor de nmda.
WO2022129047A3 (en) Modulators of the nmda receptor
JOP20210091A1 (ar) مشتقات أريل سلفونيل بيرول كربوكساميد على هيئة عوامل تنشيط قناة بوتاسيوم Kv3
MX2020009097A (es) Compuestos que modulan la funcion del receptor de ampa.
MX2019011023A (es) Diarilureas como moduladores alostéricos de cannabinoide cb1.
MX2024005123A (es) Moduladores del receptor ccr6.
ZA202306305B (en) Pharmaceutical compounds
MX2022006776A (es) Composiciones farmaceuticas oftalmicas.